Titre :
|
Clinical goals and performance measures for cholesterol management in secondary prevention of coronary heart disease. (2000)
|
Auteurs :
|
T.H. LEE ;
J.I. CLEEMAN ;
C. GILLETT ;
S.M. GRUNDY ;
R.C. PASTERNAK ;
J. SEIDMAN ;
C. SENNETT ;
Harvard Medical School. Boston. USA ;
National Committee for Quality Assurance. Washington. DC. USA
|
Type de document :
|
Article
|
Dans :
|
JAMA - Journal of the american medical association (vol. 283, n° 1, 2000)
|
Pagination :
|
94-98
|
Langues:
|
Anglais
|
Mots-clés :
|
Cardiopathie coronaire
;
Politique santé
;
Prévention santé
;
Contrôle
;
Cholestérol
;
Objectif
;
Homme
;
Appareil circulatoire [pathologie]
;
Métabolisme [pathologie]
|
Résumé :
|
[BDSP. Notice produite par INIST R0xA3r3m. Diffusion soumise à autorisation]. Guidelines from the National Cholesterol Education Program (NCEP) recommend reduction of low-density lipoprotein cholesterol (LDL-C) to 100 mg/dL (2.59 mmol/L) or less in patients with established coronary heart disease (CHD). However, the National Committee for Quality Assurance (NCQA) is implementing a new performance measure as part of the Health Plan Employer and Data Information Set (HEDIS) that appears to endorse a different target. The new HEDIS measure will require managed care organizations seeking NCQA accreditation to measure and report the percentage of patients who have had major CHD events who achieve LDL-C levels less than 130 mg/dL (3.36 mmol/L) between 60 and 365 days after discharge. These different LDL-C thresholds emphasize the difference between a clinical goal for the management of individual patients (
|